Early trial checks safety of targeted cancer drug in chinese patients
NCT ID NCT05382364
First seen Feb 21, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This early-phase study tests the safety of a drug called tucatinib in about 25 Chinese patients with advanced HER2+ breast, stomach, or colorectal cancers that have stopped responding to standard treatments. The main goal is to see what side effects occur and how the drug moves through the body. This is not a cure; it aims to control the disease while managing risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, 201321, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hunan Cancer Hospital
Changsha, Hunan, 421000, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, 300060, China
Conditions
Explore the condition pages connected to this study.